Viewing nowCombinationLodivica Tablets 2.5/40 mg (Amlodipine Nicotinate, Olmesartan Medoxomil)
S-Amlodipine Nicotinate 3.253mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Hanlim Pharmaceutical Co., Ltd.

MFDS item code 201404534 · Approved 2014.09.30 · Insurance code 645305010
Treatment of essential hypertension not controlled with monotherapy
This medication is used for patients with essential hypertension. It is prescribed when blood pressure control is insufficient with monotherapy using Amlodipine (Amlodipine) or Olmesartan Medoxomil. It effectively lowers blood pressure, reducing the risk of cardiovascular diseases. Proper management of hypertension helps to improve the overall health status of the patients. This drug plays an important role in stabilizing blood pressure.
This medicine should be taken once daily as 1 tablet with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before starting this medicine, it is recommended that the dose be adjusted using the individual components (S-amlodipine (amlodipine) or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 5/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into consideration. The recommended doses are as follows. - 2.5/20 mg: For patients whose blood pressure is not adequately controlled with S-amlodipine 2.5 mg (amlodipine 5 mg) or olmesartan medoxomil 20 mg monotherapy. - 5/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 2.5/40 mg: For patients whose blood pressure is not adequately controlled with 2.5/20 mg. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 2.5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective circulating blood volume: In patients who may have reduced effective circulating blood volume (Intravascular volume depletion) (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended that treatment be initiated at a low dose with careful monitoring of their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive agents and/or diuretics should be closely monitored for blood pressure and renal function. This medicine should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medicine under Precautions for Use.) ∘Elderly patients: Treatment is generally initiated at a low dose. When adjusting the dose, the patient's renal or cardiac function and coexisting diseases should be taken into consideration. Blood pressure should be monitored closely and more frequently in elderly patients.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm to the fetus and newborn if taken during the second or third trimester of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients allergic to any components of this medication or similar drugs, pregnant or breastfeeding women, patients with severe liver or heart disease, or patients undergoing kidney dialysis should not take it. Patients with a deficiency in fluids or salts may experience hypotension, so close monitoring of their condition is required during the initial dosage, and appropriate actions should be taken if hypotension is observed. There is a risk of severe hypotension due to sudden dilation of blood vessels, particularly in patients with aortic stenosis, who should exercise caution. Patients with weakened hearts should be closely monitored for worsening of heart failure symptoms while taking this medication. Patients with impaired kidney function may have their kidney function affected by this medication, so regular kidney function tests should be conducted. Patients with reduced liver function may experience delayed metabolism of this medication, requiring caution during use. Common side effects may include dizziness, headache, hypotension, edema, dyspepsia, rash, etc.; if any unusual symptoms occur, consult a healthcare professional. Interactions may occur when this medication is taken with other drugs, so it is essential to inform healthcare providers of any other medications being taken. Especially, grapefruit juice can excessively enhance the blood pressure-lowering effect, so it is advisable to avoid it. This medication should not be used during pregnancy unless necessary, and if pregnancy is being planned or confirmed, prompt consultation with a healthcare provider is advised. Nursing women should either discontinue breastfeeding or this medication, as it may be transmitted through breast milk. Children under 18 years should refrain from taking this medication as its safety and efficacy have not been established for this age group. Elderly patients, who may have decreased liver, kidney, or heart function, should start on a lower dose and be observed carefully. In cases of overdose, blood pressure may be excessively low or heart rate may increase; immediate medical attention is necessary for appropriate treatment. This medication should be kept out of reach of children and stored away from moisture, heat, and direct sunlight.
Drug hypersensitivity, hyperkalemia, decreased libido, dizziness, headache, orthostatic hypotension, drowsiness, paresthesia, reduced sensation, syncope, vertigo, palpitations, rapid pulse, hypotension, orthostatic hypotension, dyspnea, cough, nausea, vomiting, dyspepsia, diarrhea, constipation, dry mouth, abdominal pain, rash, urticaria, muscle stiffness, limb pain, low back pain, frequent urination, erectile dysfunction, peripheral edema, edema, dependent edema, fatigue, asthenia, facial edema, decreased serum potassium, increased serum creatinine, increased serum uric acid, increased gamma-glutamyl transferase, decreased hemoglobin, decreased hematocrit, low back pain, bronchitis, increased creatine phosphokinase, hematuria, hyperglycemia, hypertriglyceridemia, influenza-like symptoms, pharyngitis, rhinitis, sinusitis, asthenia, vascular edema, chronic malabsorption syndrome-like intestinal disease, intestinal vascular edema, rhabdomyolysis, acute renal failure, elevated serum creatinine, hair loss, itching, urticaria, autoimmune hepatitis, flushing, fatigue, edema, palpitations, dizziness, headache, drowsiness, abdominal pain, nausea, gynecomastia, jaundice, elevated liver enzymes, leukopenia, thrombocytopenia, toxic epidermal necrolysis, hypotension, tachycardia, bradycardia
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, thus it must be stored in a tightly sealed container. Additionally, it is best to keep it at room temperature between 1°C to 30°C, avoiding excessively hot or cold places.
Pale yellow round film-coated tablets
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationS-Amlodipine Nicotinate 3.253mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Hanlim Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Nicotinate 6.506mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Hanlim Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Nicotinate 3.253mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Hanlim Pharmaceutical Co., Ltd.
CombinationS-Amlodipine Nicotinate 6.506mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Hanlim Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.